ISRCTN99682126进行中（未招募）1 期
A phase 1b dose escalation and dose expansion study evaluating the safety, pharmacokinetics, and antitumor activity of furmonertinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR or HER2 mutations, including exon 20 insertion mutations
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 108
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Signed Informed Consent Form
- •2. Age =18 years at time of signing Informed Consent Form
- •3. Ability to comply with the study protocol, in the investigator’s judgment
- •4. Measurable disease per RECIST v1.1
- •5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •6. Life expectancy of = 12 weeks
- •7. Adequate hematologic and organ function within 14 days prior to initiation of study treatment
- •8. For women of childbearing potential (WOCBP): Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating eggs
- •9. For men who are not surgically sterile: Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating sperm
- •10. Patients with a history of treated CNS metastases or new asymptomatic CNS metastases detected at screening
- •11. Histologically or cytologically documented, locally advanced or metastatic NSCLC not amenable to curative surgery or radiotherapy
- •12. Consent to provide tumor tissue specimen (paraffin-embedded tissue block or 15 serial-cut slides)
- •13. Disease that has progressed after at least one available standard therapy; or for whom standard therapy has proven to be ineffective or intolerable; or for whom a clinical trial of an investigational agent is a recognized standard of care
- •14. Documented radiologic disease progression during or after the last systemic antitumor therapy before the first dose of the investigational product (furmonertinib)
- •15. For patients with EGFR mutations sensitive to osimertinib, the patient must have received osimertinib prior to study enrollment in regions where osimertinib is approved, including the US
- •Stage 1 Dose Escalation and Backfill Cohorts Inclusion Criteria:
- •16. Documented validated results from local testing of blood or tumor tissue confirming the presence of an EGFR Exon 20 insertion mutation, HER2 Exon 20 insertion mutation, or EGFR activating mutation (including Exon 19 and Exon 21 mutations such as G719X, Exon 19 deletion, L858R, L861Q) or EGFR T790M mutation
- •17. For patients with NSCLC with EGFR Exon 20 insertion mutations or HER2 Exon 20 insertion mutations, the patient must have experienced disease progression (during or after treatment) or have intolerance to treatment with platinum-based chemotherapy
- •18. For patients with NSCLC with EGFR activating mutations other than Exon 20 insertion mutations, the patient must have experienced disease progression (during or after treatment) with the standard of care EGFR TKI
- •Stage 2 Cohort 1 Inclusion Criteria:
- •19. Documented validated results from either local testing of blood or tumor tissue confirming the presence of EGFR Exon 20 insertion mutations
- •20. The patient must have experienced disease progression (during or after treatment) or have intolerance to treatment with platinum-based chemotherapy
- •Stage 2 Cohort 2 Inclusion Criteria:
- •21. Documented validated results from either local testing of blood or tumor tissue confirming the presence of HER2 Exon 20 Insertion Mutations
- •22. The patient m
排除标准
- •1. Inability or unwillingness to swallow pills
- •2. Inability to comply with study and follow-up procedures
- •3. Malabsorption syndrome or other condition that would interfere with enteral absorption
- •4. Pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures biweekly or more frequently
- •5. Severe acute or chronic infections
- •6. In the setting of a pandemic or epidemic, screening for active infections should be considered according to local or institutional guidelines or those of applicable professional societies
- •7. Previous interstitial lung disease (ILD), drug-induced interstitial lung disease, radiation pneumonitis requiring steroid therapy; or having the clinical manifestations of suspected ILD.
- •8. History of or active clinically significant cardiovascular dysfunction
- •9. Mean resting corrected QT interval (QTcF) > 470 msec, obtained from triplicate ECGs, using the screening clinic ECG machine derived QTcF value.
- •10. Clinically significant prolonged QT interval or other arrhythmia or clinical status considered by investigators that may increase the risk of prolonged QT interval or current use of the drugs that may lead to prolonged QT interval
- •11. Uncontrolled hypercalcemia (> 1.5 mmol/L ionized calcium or calcium > 12 mg/dL or corrected serum calcium = ULN) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab.
- •12. Significant traumatic injury or major surgical procedure within 4 weeks prior to Day 1 of Cycle 1.
- •13. Patients with chronic diarrhea, short bowel syndrome or significant upper gastrointestinal surgery including gastric resection, a history of inflammatory bowel disease or any active bowel inflammation (including diverticulitis)
- •14. Any other diseases, active or uncontrolled pulmonary dysfunction, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of furmonertinib, that may affect the interpretation of the results, or renders the patients at high risk from treatment complications
- •15. Treatment with chemotherapy, immunotherapy, biologic therapy, or an investigational agent as anti-cancer therapy within 3 weeks or five half-lives prior to initiation of furmonertinib, whichever is shorter, or endocrine therapy within 2 weeks prior to initiation of furmonertinib
- •16. Radiation therapy (other than palliative radiation to bony metastases and radiation to CNS metastases as described above) as cancer therapy within 4 weeks prior to initiation of furmonertinib
- •17. Palliative radiation to bony metastases within 2 weeks prior to initiation of furmonertinib
- •18. Adverse events from prior anti-cancer therapy that have not resolved to Grade = 1 except for alopecia or Grade = 2 peripheral neuropathy
- •19. History of other malignancy within 3 years prior to screening, with the exception of patients with a negligible risk of metastasis or death and/or treated with expected curative outcome
- •20. Pregnant, breastfeeding, or intending to become pregnant during the study or within 60 days after the final dose of furmonertinib
- •21. Known or
研究者
相似试验
尚未招募
不适用
A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Activating EGFR or HER2 MutationsPatients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with mutations in a gene called epidermal growth factor receptor (EGFR)/Lung Cancer10038666NL-OMON53437ArriVent BioPharma, Inc.5
招募中
1 期
A Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutationson-small cell lung cancer harboring activating EGFR or HER2 kinase domain mutationsJPRN-jRCT2031220455Isui Ayako15
尚未招募
1 期
A phase 1a/b dose-escalation and dose-expansion study to evaluate Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising Capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC)metastatic castration-resistant prostate cancerCancer - ProstateACTRN12623001072606South Metropolitan Health Service (SMHS)45
招募中
1 期
Tucatinib plus trastuzumab and oxaliplatin-based chemotherapy or pembrolizumab-containing combinations for HER2+ gastrointestinal cancersColorectal adenocarcinoma (CRC), Gastric adenocarcinoma, GEJ adenocarcinoma,JPRN-jRCT2031220143Mayor JoAl40
尚未招募
1 期
A Study of the Combination of Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple MyelomaMultiple MyelomaJPRN-jRCT2031230640Fujikawa Ei164